Stamulumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Clinical data | |
| Routes of administration | injection only |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Formula | C6330H9748N1672O1668S48 |
| Molar mass | 137500.53 g·mol−1 |
Stamulumab (MYO-029[1]) is an experimental myostatin inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy. MYO-029 was formulated and tested by Wyeth in Collegeville, Pennsylvania.[2] Myostatin is a protein that inhibits the growth of muscle tissue, MYO-029 is a recombinant human antibody designed to bind to and inhibit the activity of myostatin.[3]
Stamulumab is a G1 immunoglobulin antibody which binds to myostatin and prevents it from binding to its target site, thus inhibiting the growth-limiting action of myostatin on muscle tissue. Research completed in 2002 found that Stamulumab might one day prove to be an effective treatment for Duchenne muscular dystrophy[4]
Phase 1 and 2 trials
- Wyeth undertook a Phase 1 and 2 clinical trial in 2005 and 2006 of MY0-029. The multiple ascending dose trial (36 patients per cohort) contained some measures of efficacy. The trial's participants included people afflicted with Facioscapulohumeral muscular dystrophy, Becker's muscular dystrophy, and Limb-girdle muscular dystrophy. Through 2007 Wyeth has been analyzing the results but the hoped-for news and/or a publication in 2007 did not occur. [2][5][6]. However, as of January 24, 2008, the study has been accepted by a peer-reviewed journal and publication is expected "in the next few months"[7]
11 March 2008 http://www.mda.org/research/080311md_myo-029.html Wyeth Won't Develop MYO-029 for MD but will continue to explore myostatin inhibition along with other strategies.
Related
- ACVR2B is similar to Stamulumab but is not an antibody; rather, it provides a portion of the molecule to which myostatin would normally bind thus preventing the myostatin from binding with the actual molecule[8].
References
- ^ Wyeth Product Pipeline, Wyeth, Website accessed April 22, 2007
- ^ a b NIH's ClinicalTrials.gov, Study Evaluating MYO-029 in Adult Muscular Dystrophy, record last updated January 24, 2007
- ^ medicalnewstoday.com, Wyeth Initiates Clinical Trial with Investigational Muscular Dystrophy Therapy MYO-029, Article Date: 28 Feb 2005 - 7:00 PDT
- ^ Blocking Myostatin Proves Beneficial in Mice with DMD, MDA Research News, 11/27/2002
- ^ Wyeth Analyzing MYO-029 Results, Muscular Dystrophy Association announcement, December 4, 2006
- ^ FSH Watch Newsletter, pg 11, FSH Society, Summer 2007
- ^ Pharma Company Responds to WiSci on Muscle-Building Drug, Wired Science, Alexis Madrigal, January 24, 2008, 2008, 4:26:27 PM
- ^ New Myostatin Blocker Makes Mouse Muscles 60 Percent Larger, MDA Research News, January 6, 2006
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
| Types | |
|---|---|
| National/International Organizations | |
| National/International Events |
|
| Clinical trials | |
